Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion
- First Online:
- 493 Downloads
Lipid nanoemulsions (LDE) may be used as carriers of paclitaxel (PTX) and etoposide (ETP) to decrease toxicity and increase the therapeutic action of those drugs. The current study investigates the combined chemotherapy with PTX and ETP associated with LDE.
Four groups of 10–20 B16F10 melanoma-bearing mice were treated with LDE-PTX and LDE-ETP in combination (LDE-PTX + ETP), commercial PTX and ETP in combination (PTX + ETP), single LDE-PTX, and single LDE-ETP. PTX and ETX doses were 9 μmol/kg administered in three intraperitoneal injections on three alternate days. In two control groups mice were treated with saline solution or LDE alone. Tumor growth, metastasis presence, cell-cycle distribution, blood cell counts and histological data were analyzed. Toxicity of all treatments was evaluated in mice without tumors.
Tumor growth inhibition was similarly strong in all treatment groups. However, there was a greater reduction in the number of animals bearing metastases in the LDE-PTX + ETP group (30 %) in comparison to the PTX + ETP group (82 %, p < 0.05). Reduction of cellular density, blood vessels and increase of collagen fibers in tumor tissues were observed in the LDE-PTX + ETP group but not in the PTX + ETP group, and in both groups reduced melanoma-related anemia and thrombocytosis were observed. Flow cytometric analysis suggested that LDE-PTX + ETP exhibited greater selectivity to neoplastic cells than PTX-ETP, showing arrest (65 %) in the G2/M phase of the cell cycle (p < 0.001). Toxicity manifested by weight loss and myelosuppression was markedly milder in the LDE-PTX + ETP than in the PTX + ETP group.
LDE-PTX + ETP combined drug-targeting therapy showed markedly superior anti-cancer properties and reduced toxicity compared to PTX + ETP.
KeywordsNanoparticles Drug-targeting Emulsions Cholesterol Low-density lipoprotein (LDL) receptors Cancer treatment
- 2.R.C. Maranhão, B. Garicochea, E.L. Silva, P. Dorlhiac-Llacer, F.J.C. Pileggi, D.A.F. Chamone, Increased plasma removal of microemulsions resembling the lipid phase of low-density lipoproteins (LDL) in patients with acute myeloid leukemia: a possible new strategy for the treatment of the disease. Braz. J. Med. Biol. Res. 25, 1003–1007 (1992)PubMedGoogle Scholar
- 4.R.C. Maranhão, B. Garicochea, E.L. Silva, P. Dorlhiac-Llacer, S.M.S. Cadena, I.J.C. Coelho, J.C. Meneguetti, F.J.C. Pileggi, D.A.F. Chamone, Plasma kinetics and biodistribution of a lipid emulsion resembling low density lipoprotein in patients with acute leukemia. Cancer Res. 54, 4660–4666 (1994)PubMedGoogle Scholar
- 9.S. Vitols, B. Angelin, S. Ericsson, G. Gahrton, G. Juliusson, M. Masquelier, C. Paul, C. Peterson, M. Rudling, K. Soderberg-Reid, V. Tidefelt, Uptake of low-density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc. Nati. Acad. Sci. USA 87, 2598–2602 (1990)CrossRefGoogle Scholar
- 12.T. Nakagawa, Y. Ueyama, S. Nozaki, S. Yamashita, M. Menju, T. Funahashi, K. Kameda-Takemura, M. Kubo, K. Tokunaga, T. Tanaka, Marked hypocholesterolemia in a case with adrenal adenoma-enhanced catabolism of low density lipoprotein (LDL) via the LDL receptors of tumor cells. J. Clin. Endocrinol. Metab. 80, 92–96 (1995)PubMedCrossRefGoogle Scholar
- 15.R.C. Maranhão, S.R. Graziani, N. Yamaguchi, R.F. Melo, M.C. Latrilha, D.G. Rodrigues, R.D. Couto, R. Schreiber, A.C. Buzaid, Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother. Pharmacol. 49, 487–498 (2002). doi:10.1007/s00280-002-0437-3 PubMedCrossRefGoogle Scholar
- 16.V.T. Hungria, M.C. Latrilha, D.G. Rodrigues, S.P. Bydlowski, C.S. Chiattone, R.C. Maranhão, Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother. Pharmacol. 53, 51–60 (2004). doi:10.1007/s00280-003-0692-y PubMedGoogle Scholar
- 17.K.V. Pinheiro, V.T. Hungria, E.S. Ficker, C.J. Valduga, C.H. Mesquita, R.C. Maranhão, Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin’s and non-Hodgkin’s lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. Cancer Chemother. Pharmacol. 57, 624–630 (2005). doi:10.1007/s00280-005-0090-8 PubMedCrossRefGoogle Scholar
- 19.L.A. Pires, R. Hegg, E.R. Freitas, E.R. Tavares, C.P. Almeida, E.C. Baracat, R.C. Maranhão, Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer. Braz. J. Med. Biol. Res. 45, 557–564 (2012). doi:10.1590/S0100-879X2012007500068 PubMedCrossRefGoogle Scholar
- 20.C.H. Azevedo, J.P. Carvalho, C.J. Valduga, R.C. Maranhão, Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma. Gynecol. Oncol. 97, 178–182 (2005). doi:10.1016/j.ygyno.2004.12.015 PubMedCrossRefGoogle Scholar
- 21.M.L. Dias, J.P. Carvalho, D.G. Rodrigues, S.R. Graziani, R.C. Maranhão, Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother. Pharmacol. 59, 105–111 (2007). doi:10.1007/s00280-006-0252-3 PubMedCrossRefGoogle Scholar
- 22.L.A. Pires, R. Hegg, C.J. Valduga, S.R. Graziani, D.G. Rodrigues, R.C. Maranhão, Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother. Pharmacol. 63, 281–287 (2009). doi:10.1007/s00280-008-0738-2 PubMedCrossRefGoogle Scholar
- 26.D.G. Rodrigues, D.A. Maria, D.C. Fernandes, C.J. Valduga, R.D. Couto, O.C. Ibanez, R.C. Maranhão, Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother. Pharmacol. 55, 565–576 (2005). doi:10.1007/s00280-004-0930-y PubMedCrossRefGoogle Scholar
- 27.R.S. Teixeira, C.J. Valduga, L.A. Benvenutti, S. Schreier, R.C. Maranhão, Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors. J. Pharm. Pharmacol. 60, 1287–1295 (2008). doi:10.1211/jpp/60.10.0004 PubMedCrossRefGoogle Scholar
- 30.R.I. Geran, N.H. Greenberg, M.M. Macdonald, A.M. Schumacher, B.J. Abbott, Protocols for screening chemical agents and natural products against animal tumors and other biological systems, 3rd edn. (National Institute of Health, Bethesda, 1972), pp. 47–51Google Scholar
- 33.L.C. van Kempen, J. Rijntjes, I. Mamor-Cornelissen, S. Vincent-Naulleau, M.J. Gerritsen, D.J. Ruiter, M.C. van Dijk, C. Geffrotin, G.N. van Muijen, Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. Int. J. Cancer 122, 1019–1029 (2008). doi:10.1002/ijc.23147 PubMedCrossRefGoogle Scholar
- 34.K.P. Claffey, L.F. Brown, L.F. del Aguila, K. Tognazzi, K.T. Yeo, E.J. Manseau, H.F. Dvorak, Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 56, 172–181 (1996)PubMedGoogle Scholar